Privigen 100 mg/ml solution for infusion clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies
This study looks at treating painful nerve damage in people with Sjögren's syndrome. It tests a medicine called Privigen against a dummy treatment to see if it reduces pain and improves daily life.
France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Influencing Progression of Airway Disease in Primary Antibody Deficiency
This study looks at people with primary antibody deficiency to see if a higher dose of immunoglobulin (Ig) replacement therapy can slow down lung problems. We'll compare lung changes over two years using scans and other health measures. This could help improve treatment for these conditions.
Netherlands - AuthorisedPhase II and Phase III (Integrated)
Effect of intravenous immunoglobulins on painful sensory neuropathy evaluated by aggregated N-of-one trials
This study is testing if a medicine called intravenous immunoglobulins (IVIG) can help reduce pain in people with nerve conditions that cause pain. We're comparing it to an inactive treatment (placebo) to see how well it works and if it's safe.
For: Idiopathic painful small fiber neuropathy or sensory neuronopathy.Norway - Ongoing, recruitingPhase III and phase IV (Integrated)
Randomized, parallel study of subcutaneous versus intravenous immunoglobulin in treatment-naïve patients with chronic inflammatory demyelinating polyneuropathy
This study compares two ways of giving an important medicine for a nerve condition called CIDP. One way is an injection under the skin, and the other is through a drip into a vein. It looks at how well each method improves daily activities and muscle strength.
For: Chronic inflammatory demyelinating polyneuropathy (CIDP)Denmark - AuthorisedTherapeutic exploratory (Phase II)
Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone for Coronavirus Disease 2019 (COVID-19) in Patients with Severely Impaired B-cell Function
This study is testing a medicine called Privigen for people with COVID-19 who have a weakened immune system. It aims to see if adding Privigen to standard care helps them recover better than standard care alone.
For: COVID-19 and Severely Impaired B-cell FunctionSweden